Galena to receive EU patent for breast-cancer vaccine

|About: Galena Biopharma, Inc. (GALE)|By:, SA News Editor

The European Patent Office notifies Galena Biopharma (GALE +7.6%) that it intends to grant a patent that covers the use of the company's NeuVax drug as a vaccine for the prevention of relapse in breast-cancer patients.

The patent is due to expire in April 2028. (PR)